Michael T Mccabe

List of Publications by Year
in descending order

26 papers	4,896 citations	361413 20 h-index	552781 26 g-index
27 all docs	27 docs citations	27 times ranked	8265 citing authors

#	Article	IF	Citations
1	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012, 492, 108-112.	27.8	1,558
2	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
3	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2989-2994.	7.1	445
4	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, 2019, 36, 385-401.e8.	16.8	359
5	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Medicinal Chemistry Letters, 2012, 3, 1091-1096.	2.8	332
6	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nature Communications, 2015, 6, 6051.	12.8	281
7	Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell, 2019, 36, 100-114.e25.	16.8	196
8	Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Science Translational Medicine, 2017, 9, .	12.4	165
9	Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Scientific Reports, 2018, 8, 9711.	3.3	128
10	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	99
11	Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Scientific Reports, 2017, 7, 17993.	3.3	85
12	EZH2 as a potential target in cancer therapy. Epigenomics, 2014, 6, 341-351.	2.1	84
13	Dnmt1 has de novo activity targeted to transposable elements. Nature Structural and Molecular Biology, 2021, 28, 594-603.	8.2	83
14	Targeting Histone Methylation in Cancer. Cancer Journal (Sudbury, Mass), 2017, 23, 292-301.	2.0	54
15	Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica, 2019, 104, 1156-1167.	3.5	50
16	CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell, 2018, 33, 1111-1127.e5.	16.8	48
17	A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics, 2014, 13, 3062-3073.	4.1	44
18	<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor. Haematologica, 2021, 106, 1979-1987.	3.5	41

#	Article	IF	Citations
19	Signaling function of PRC2 is essential for TCR-driven T cell responses. Journal of Experimental Medicine, 2018, 215, 1101-1113.	8.5	40
20	MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. Oncogenesis, 2018, 7, 35.	4.9	28
21	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	23
22	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10772-10805.	6.4	17
23	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery, 2022, 12, 2120-2139.	9.4	14
24	Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors. Structure, 2022, 30, 793-802.e5.	3.3	11
25	A Chemical Acetylation-Based Mass Spectrometry Platform for Histone Methylation Profiling. Molecular and Cellular Proteomics, 2021, 20, 100067.	3.8	3
26	Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1. Communications Biology, 2022, 5, .	4.4	2